Invivyd, Inc. (IVVD)

↓ Download CSV

CIK 0001832038 · Nasdaq · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Invivyd, Inc. reported revenue of $53.43M, up 110.5% from the prior year. The company ran a net loss, with a net margin of -98.2%. It held $276.88M in total assets against $35.34M in total liabilities.

Key ratios (FY2025)

-104.0%
Operating margin
-98.2%
Net margin
-21.7%
Return on equity
+110.5%
Revenue growth (YoY)
Metric (FY)202520242023202220212020
Revenue$53.43M$25.38M$0
Operating Income-$55.56M-$176.88M-$212.76M-$248.03M-$226.91M
Net Income-$52.49M-$169.93M-$198.64M-$241.32M-$226.79M
EPS (Diluted)$-0.30$-1.43$-1.81$-2.23$-5.32
Total Assets$276.88M$129.51M$229.18M$383.17M$620.09M$117.38M
Total Liabilities$35.34M$61.98M$51.71M$27.20M$62.07M$13.08M
Shareholders' Equity$241.54M$67.54M$177.47M$355.97M$558.02M-$65.25M
Cash & Equivalents$226.69M$69.35M$200.64M$92.08M$542.22M$114.99M
Operating Cash Flow-$58.13M-$170.49M-$173.16M-$219.99M-$184.74M
Capital Expenditures$155.0K$140.0K$615.0K$1.71M$84.0K
Shares Outstanding281.99M119.84M110.16M109.04M110.78M5.59M